Kenvue Inc. KVUE

Revenue Intelligence Report • 15 quarters of SEC filing data • Updated 2026-03-15

Kenvue Inc. has a forecasted full-year revenue of $15B, a -1.4% year-over-year change, based on 15 quarters of SEC filing data. Key revenue drivers include R&D (elasticity 0.06x) and SG&A (elasticity 0.23x). The ARDL model achieves strong accuracy at 0.4% MAPE.

Investment Thesis

Our ARDL model tracks Kenvue Inc.'s revenue with exceptional precision (0.4% MAPE), indicating highly predictable cash flows. R&D investment shows a 0.06x multiplier — each 1% increase in R&D spend is associated with a 0.06% revenue increase, signaling strong innovation-to-revenue conversion. Sales & marketing spend shows a 0.23x elasticity, suggesting effective go-to-market execution.

Next FY Revenue
$14.9B
-1.4% YoY
R&D Elasticity
0.06x
SG&A Elasticity
0.23x
Model Accuracy
0.4% MAPE
Holdout validation: The model predicted $3.8B vs the actual $3.8B — an error of 0.3%.

Revenue Forecast

KVUE Revenue Forecast

Quarterly Detail

QuarterModel ForecastActual95% RangeYoY GrowthStatus
Q4 2025 $3.8B $3.8B $3.8B – $3.8B +3.5% ✓ In range
Q1 2026 $3.8B $3.7B – $3.8B +0.4%
Q2 2026 $3.7B $3.7B – $3.8B -2.8%
Q3 2026 $3.7B $3.6B – $3.8B -1.2%
Q4 2026 $3.7B $3.6B – $3.8B -1.9%

Seasonal Factors

Multiplicative seasonal adjustment: These factors capture Kenvue Inc.'s systematic quarterly revenue patterns relative to the trend model. A factor of 1.05 means that quarter typically runs 5% above the underlying trend; 0.95 means 5% below. Factors are computed as the median of (actual / fitted) across all available quarters.
Fiscal QuarterSeasonal Factorvs TrendInterpretationObs.
FQ1 (Sep–Nov) 1.0021 +0.2% In line with trend 4
FQ2 (Dec–Feb) 0.9973 -0.3% In line with trend 3
FQ3 (Mar–May) 0.9994 -0.1% In line with trend 3
FQ4 (Jun–Aug) 1.004 +0.4% In line with trend 3

How Spending Drives Revenue

KVUE Spending Timing
Reading this chart: Each line shows the cumulative elasticity — how a 1% increase in spending translates to revenue growth over subsequent quarters. The effect builds over 4-5 quarters as investments compound.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch

More in Healthcare

MCK RMD STE CNC CAH ISRG PFE DGX